Neurophth and AAVnerGene partner on AAV capsids for next-gen ophthalmic gene therapy
January 19th 2021Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.
Read More
Collaboration formed to develop AAV-based gene therapies for eye disease
January 6th 2021ViGeneron and Biogen this week have announced a global collaboration and licensing agreement in which the partners will develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors that treat inherited eye disease.
Read More